Earnings

Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026

Oct 26, 2026 · 08:49 AM ET· updated 2h ago

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.Ex vivo data in two models of recent cosmetic surgery explants showed visible improvements in fine

Why It Matters

Azitra is showing early test results for a wrinkle cream at a big conference. The company expects to share human study results by the end of 2026.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

AZTR1.58

+0.69 (+76.56%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.